Skip to main content

Table 4 Base case results from the healthcare perspective and patient perspective (unit: RMB)

From: Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis

 

Doc-ADT

Abi-ADT

Difference

Healthcare perspective

 Drug + ADT costs

¥130,786

¥1,230,951

(¥1,100,165)

 Medical costs

¥29,098

¥31,339

(¥2,241)

 AE costs

¥266

¥1,459

(¥1,193)

 2nd-line Tx costs

¥239,694

¥23,152

¥216,542

 Total

¥399,844

¥1,286,900

(¥887,057)

 

Cost saving

Patient perspective

 Drug + ADT costs

¥27,611

¥307,738

(¥280,127)

 Medical costs

¥6,459

¥7,835

(¥1,376)

 AE costs

¥40

¥365

(¥325)

 2nd-line Tx costs

¥59,091

¥3,473

¥55,618

 Total

¥93,200

¥319,410

(¥226,210)

 

Cost saving

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us